9 METERS BIOPHARMA, INC.

2022 Q1 Form 10-Q Financial Statement

#000155198622000044 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.24M $38.50M
YoY Change -3.27% 1341.95%
Cash & Equivalents $37.24M $38.50M
Short-Term Investments
Other Short-Term Assets $1.846M $1.490M
YoY Change 23.86% 161.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.09M $39.98M
YoY Change -2.24% 1137.53%
LONG-TERM ASSETS
Property, Plant & Equipment $17.31K $15.09K
YoY Change 14.68% -25.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K
YoY Change 0.0% 0.0%
Total Long-Term Assets $176.5K $223.9K
YoY Change -21.17% 309.44%
TOTAL ASSETS
Total Short-Term Assets $39.09M $39.98M
Total Long-Term Assets $176.5K $223.9K
Total Assets $39.26M $40.21M
YoY Change -2.35% 1123.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.912M $1.371M
YoY Change 39.48% -72.99%
Accrued Expenses $6.256M $4.566M
YoY Change 37.0% -5.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.224M $5.987M
YoY Change 37.37% -62.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $98.39K $150.0K
YoY Change -34.41%
Total Long-Term Liabilities $98.39K $150.0K
YoY Change -34.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.224M $5.987M
Total Long-Term Liabilities $98.39K $150.0K
Total Liabilities $8.323M $6.142M
YoY Change 35.5% -61.23%
SHAREHOLDERS EQUITY
Retained Earnings -$180.2M -$137.5M
YoY Change 31.06% 85.38%
Common Stock $25.82K $21.63K
YoY Change 19.38% 423.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.94M $34.07M
YoY Change
Total Liabilities & Shareholders Equity $39.26M $40.21M
YoY Change -2.35% 1123.74%

Cashflow Statement

Concept 2022 Q1 2021 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37797
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
CY2022Q1 dei City Area Code
CityAreaCode
919
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
275-1933
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
CY2022Q1 dei Trading Symbol
TradingSymbol
NMTR
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q4 us-gaap Assets Current
AssetsCurrent
49985233 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17309 USD
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
259107380 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37242112 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46993285 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1845500 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2991948 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
39087612 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16094 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153646 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166618 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2022Q1 us-gaap Assets
Assets
39264147 USD
CY2021Q4 us-gaap Assets
Assets
50173525 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1911793 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434452 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6255933 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56457 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54796 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8224183 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8457070 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98390 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113142 USD
CY2022Q1 us-gaap Liabilities
Liabilities
8322573 USD
CY2021Q4 us-gaap Liabilities
Liabilities
8570212 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
258235418 shares
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8368478 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3190302 USD
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
258235418 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
25824 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
25824 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
211108156 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
210418156 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180192406 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168840667 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30941574 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39264147 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50173525 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2995771 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2208800 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11364249 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5399102 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11364249 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5399102 USD
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
12814 USD
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
5087 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
304 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
44064 USD
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12510 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31977 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11351739 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5431079 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258235418 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
258235418 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
211280867 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
211280867 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41603313 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30941574 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
422000 USD
CY2021Q1 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
6857028 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75903 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11351739 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
690000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
422000 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 USD
CY2022Q1 us-gaap Depreciation
Depreciation
1627 USD
CY2021Q1 us-gaap Depreciation
Depreciation
1110 USD
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1146448 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
269942 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-522659 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-117269 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
287992 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-866315 USD
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2021Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9748331 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6225000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5012 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2842 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5012 USD
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 USD
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75903 USD
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6857028 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6874732 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9751173 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
644720 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46993285 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37242112 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38496108 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
569 USD
CY2022Q1 nmtr Noncash Addition Of Stock Offering Costs
NoncashAdditionOfStockOfferingCosts
0 USD
CY2021Q1 nmtr Noncash Addition Of Stock Offering Costs
NoncashAdditionOfStockOfferingCosts
142333 USD
CY2020Q4 nmtr Sale Of Stock Shelf Registration Maximum Equity Offering Price
SaleOfStockShelfRegistrationMaximumEquityOfferingPrice
200000000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three months ended March 31, 2022. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1633295 USD
CY2022Q1 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
5010780 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1146260 USD
CY2021Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4228048 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
98893 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106479 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6255933 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5967822 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47700000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53200000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53200000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47700000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53249545 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47681586 shares
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37200000 USD
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 licenseAgreement
CY2021Q3 nmtr Milestone Payment
MilestonePayment
500000 USD
CY2021Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2022Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2021Q2 nmtr Capital Stock Authorized
CapitalStockAuthorized
560000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
550000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
258235418 shares
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
62329387 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
49417616 shares
CY2022Q1 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 equity-basedIncentivePlan
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
422000 USD
CY2022Q1 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
CY2022Q1 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2022Q1 nmtr Severance Provisions Termination Or Resignation Annual Base Salary Period
SeveranceProvisionsTerminationOrResignationAnnualBaseSalaryPeriod
P18M
CY2021Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2022Q1 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
300000 USD
CY2021Q4 nmtr Deferred Compensation Liability Severance Accrual
DeferredCompensationLiabilitySeveranceAccrual
400000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
180000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25154 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
154846 USD

Files In Submission

Name View Source Status
0001551986-22-000044-index-headers.html Edgar Link pending
0001551986-22-000044-index.html Edgar Link pending
0001551986-22-000044.txt Edgar Link pending
0001551986-22-000044-xbrl.zip Edgar Link pending
ex311q12022.htm Edgar Link pending
ex312q12022.htm Edgar Link pending
ex321q12022.htm Edgar Link pending
ex322q12022.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20220331.htm Edgar Link pending
nmtr-20220331.xsd Edgar Link pending
nmtr-20220331_cal.xml Edgar Link unprocessable
nmtr-20220331_def.xml Edgar Link unprocessable
nmtr-20220331_g1.jpg Edgar Link pending
nmtr-20220331_htm.xml Edgar Link completed
nmtr-20220331_lab.xml Edgar Link unprocessable
nmtr-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending